# RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department

> **NCT04485195** · PHASE4 · COMPLETED · sponsor: **Ottawa Hospital Research Institute** · enrollment: 350 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Vernakalant
- **DRUG:** Procainamide

## Key facts

- **NCT ID:** NCT04485195
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-17
- **Primary completion:** 2024-09-15
- **Final completion:** 2024-11-06
- **Target enrollment:** 350 (ACTUAL)
- **Last updated:** 2025-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04485195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04485195, "RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04485195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*